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Dear Editor,
We enjoyed reading the excellent article by Yilmaz and 
colleagues on noninvasive assessment of liver fibrosis us-
ing aspartate transaminase to platelet ratio index (APRI) 
in adult patients with chronic liver disease (CLD) (1). They 
performed their tests on adults with chronic hepatitis C 
(CHC), B (CHB), and non-alcoholic fatty liver disease (NA-
FLD). We definitely need to develop serological markers 
that have satisfactory sensitivity, specificity, and high pre-
dictive values, which can be used either instead of liver 
biopsy or to reduce the frequency of needed biopsies for 
monitoring the evolution of CHC and defining the right 
moment for commencing treatment. Despite the study 
results showing that APRI has an acceptable accuracy for 
the assessment of liver fibrosis in adults with CHC and 
NAFLD, this was not the case in CHB patients. We believe 
that the study results would have been more valid if the 
researchers have used a combination of non-invasive 
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tests to assess liver fibrosis. A similar study conducted in 
Hungary used APRI and liver stiffness (LS) measurements 
to assess fibrosis in CHC (2). The combination of both fi-
brosis markers was useful for non-invasive assessment 
of fibrosis in CHC. Forestier and colleagues found that LS 
measurements, APRI score, 
13C-amniopyrine breath test 
and indocyanine green plasma clearance were reliable 
markers for assessing cirrhosis in patients with CLD (3). 
APRI was also found to be a simple and readily available 
tool for assessing liver fibrosis in patients with biliary 
atresia during post-operative follow-up care (4).
A drawback for using APRI is that its performance is 
not reliable in women, younger patients and in those 
with non-vertically-transmitted hepatitis C virus infec-
tion (5). Alternatively, our group recommends the use of 
Fibrotest (FT) as a non-invasive serum biomarker for the 
assessment of the degree of hepatic fibrosis in pediatric 
patients with CHC. FT at a cutoff value of 0.25 was able 
to discriminate patients with mild stage of fibrosis from 
those with no or minimal fibrosis (sensitivity of 92.3%, 
specificity of 95.8% and accuracy of 94%). A higher cutoff 
point (FT = 0.54) can be used to diagnose significant fi-  Copyright  c 2011, BRCGL, Published by Kowsar M.P.Co  All right reserved.Hepat Mon. 2011;11(5):378-379
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brosis (ie., moderate or severe stages) with a sensitivity of 
71.4%, specificity of 90.7%, and accuracy of 88.0% (6).
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